Home -> Law Blog Directory -> Intellectual Property Law Blogs -> Orange Book Blog: At the Intersection of Patent Law and FDA Law

Intellectual Property Law

: Orange Book Blog: At the Intersection of Patent Law and FDA Law

C5 "EU Pharma Law and Regulation" Conference, Geneva, November 4-5

By Aaron Barkoff

C5 is presenting a conference next month entitled "EU Pharma Law and Regulation."  It will take place November 4-5 in Geneva, Switzerland.

According to C5, "From the EU Pharma Sector Inquiry to recent parallel trade cases, the continued growth of counterfeiting, multiple options for extending product exclusivity amidst dwindling product pipelines and blockbusters coming off-patent, C5's 'EU Pharma Law' is the only event covering the key topics shaping pharmaceutical law and practice today."

The following presentations sound particularly interesting:

• "Current and Pending Issues in EU Legislation, Regulation and Case Law"
• "Current State of Play and Legal Framework for Biosimilars"
• "Examination of the EU Pharmaceutical Sector Inquiry"
• "Examination of the Intersection Between Competition and Pharma Law:  The Inquiry, Anti-Trust and Parallel Trade"
• "Successful Patent Management and Patent Enforcement in the New EU Territories"
• "Weighing the Risks and Benefits of Expanding Into the Growing Asian Pharmaceutical Sector:  Key Considerations for European Pharma Companies"
• "Advanced Strategies for Patent and Product Life Cycle Management"
• "Choosing the Best Licensing Strategy for Every Stage of Drug Development"

In addition, two post-conference workshops are offered on November 6th:  "Developing an Effective FCPA Compliance Program in the Pharmaceutical Industry" and "A Practical Guide to Managing the PIP Approval Process and Successfully Achieving Paediatric Term Extension."

For more information or to register, please visit the conference website.

Orange Book Blog readers can save 10% by using registration code 800L09.ORANGE.

Full post as published by Orange Book Blog: At the Intersection of Patent Law and FDA Law on October 12, 2008 (boomark / email).